BiotechTube
Dianosic

Dianosic

Lyon, France· Est.
dianosic.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $21M

Overview

Dianosic is a private, clinical-stage medtech company based in Lyon, France, pioneering an intranasal drug delivery platform. Its lead technology, the DIAXX Active Resorbable Intranasal Scaffold, is in preclinical development for chronic rhinitis (DIA01-R) and chronic rhinosinusitis (DIA01-S), with a longer-term 'Nose to Brain' program targeting CNS disorders. The company is currently pre-revenue, having raised €7M in late 2025, and has already commercialized its first product, the CAVI-T balloon for epistaxis, in Europe.

Chronic RhinitisChronic RhinosinusitisEpistaxisCentral Nervous System Disorders

Technology Platform

DIAXX Active Resorbable Intranasal Scaffold: A proprietary platform of drug-eluting, long-term, resorbable polymer scaffolds for targeted, sustained intranasal drug delivery. Also exploring Nose-to-Brain (NTB) applications for CNS disorders.

Funding History

2
Total raised:$21M
Series A$18M
Seed$3M

Opportunities

The large, underserved population of chronic rhinitis and sinusitis patients who are non-adherent or non-responsive to current therapies presents a multi-billion dollar market.
Successfully leveraging the DIAXX platform for Nose-to-Brain delivery could open transformative opportunities in the vast CNS therapeutic market, representing a major strategic expansion.

Risk Factors

Key risks include the preclinical-to-clinical transition for the novel DIAXX scaffold, with potential for unfavorable safety or efficacy data.
The scientific and regulatory complexity of proving effective Nose-to-Brain delivery is high.
Finally, convincing cost-conscious healthcare systems to reimburse a procedural solution over cheap drugs poses a commercial challenge.

Competitive Landscape

In epistaxis, Dianosic competes with other balloon tamponade devices and traditional packing methods. In chronic rhinitis/sinusitis, the DIAXX platform would compete against daily drug sprays, oral medications, and more invasive surgical procedures/sinus dilation devices. Its unique value proposition is sustained, localized drug delivery via a resorbable implant.

More companies in Small Molecule Drugs →More companies in France →